• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Technology·POAI
Held by 1 Guru
Share

Axe Compute Inc. Stocks

$ 1.74Last Updated 20.03.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 1.23M

$ 1.74
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

17.10.2026 03:47

"It'll all blow over": Nvidia CEO Huang expressed confidence that the AI rally will continue

17.10.2026 03:37

"Musk Magic" Is Back: CFRA Analyst Raises Tesla's Price Target Due to the Flying Car

17.10.2026 03:20

Citi and BofA block AI agents from client accounts amid fears of deposit outflows

17.10.2026 02:40

Dollar posts worst week in over a month; euro snaps five-week losing streak

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026